Full text
1/2026
vol. 77
Short communication
Pathologic assessment of response to neoadjuvant therapy in melanoma – recommendations for the evaluation of post-resection specimens
Department of Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Department of Tumour Pathology, Maria Sklodowska-Curie Greater Poland Cancer Centre, Poznan, Poland
Chair and Department of Tumour Pathology and Prophylaxis, Poznan University of Medical Sciences, Poznan, Poland
Department of Pathology, Centre of Postgraduate Medical Education, Warsaw, Poland
Day Chemotherapy Unit, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Department of Soft Tissue, Bone, and Melanoma Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Biobank, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Pol J Pathol 2026; 77 (1): 95-101
Data publikacji online: 2026/06/09
Article file
- Pavlick AC, Ariyan CE, Buchbinder EI, Davar D, Gibney GT, Hamid O, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. J Immunother Cancer 2023; 11: e006947.
- Ellebaek E, Donia M, Svane IM. Neoadjuvant or perioperative immunotherapy for resectable melanoma: the need for biomarkers. Eur J Cancer 2025; 217: 115257.
- Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Men- zies AM, Lopez-Yurda M, et al. Neoadjuvant Nivolumab and Ipilimumab in resectable stage III melanoma. N Engl J Med 2024; 391: 1696-1708.
- Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, et al. Neoadjuvant-adjuvant or adjuvant-only Pembrolizumab in advanced melanoma. N Engl J Med 2023; 388: 813-823.
- Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol 2019; 20: 948-960.
- Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med 2022; 28: 1178-1188.
- Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol 2018; 29: 1861-1868.
- Rawson RV, Maher NG, Menzies AM, Lo SN, Mesbah Ardakani N, Jackett LA, et al. Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma. Ann Oncol 2026; 37: 206-216.
- Deutsch JS, Scolyer RA, Burton E, Busam KJ, Chen KY, Cimino-Mathews A, et al. Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort. Ann Oncol 2026; 37: 141-154.
- Meyers M, Mouna O, Langouo M. Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint? Curr Opin Oncol 2025; 37: 116-120.
Copyright: © 2026 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
